Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.

2026
PharmacoEconomics

Therapeutic Area

Back of the eye (BOTE)
Categories

Other, Sponsored/funded by Santen

Affiliations

Santen Pharmaceutical SA, the Netherlands Branch, De Entree 11-97, 1101BH, Amsterdam, Netherlands. kun.shivanwielink@santen.com; NIHR Moorfields Biomedical Research Centre, London, UK; University College London, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Santen Pharmaceutical SA, the Netherlands Branch, De Entree 11-97, 1101BH, Amsterdam, Netherlands; Santen Pharmaceuticals SA, Geneva, Switzerland; Santen Pharmaceuticals GmbH, Munich, Germany; IQVIA, London, UK.

Related Publications

Two-year prospective natural history study of EYS-associated retinitis pigmentosa using adaptive optics: the KEYS study

Masakazu H., Akiko M., Midori Y., Elena G.-S., Shohei K., Satoshi Y., Yuki T., Masanao T., Shuhei K., Yasuhiko H., Yasuo K., Kiyoko G.

Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.

STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators

View all Back of the eye (BOTE) publications